See more : Synchrony Financial (SYF-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Avantor, Inc. (AVTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avantor, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Seibu Holdings Inc. (9024.T) Income Statement Analysis – Financial Results
- Bradda Head Lithium Limited (BHL.L) Income Statement Analysis – Financial Results
- KeyStar Corp. (KEYR) Income Statement Analysis – Financial Results
- MICREED Co.,Ltd. (7687.T) Income Statement Analysis – Financial Results
- KUMHO Engineering & Construction Co., Ltd. (002995.KS) Income Statement Analysis – Financial Results
Avantor, Inc. (AVTR)
About Avantor, Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.97B | 7.51B | 7.39B | 6.39B | 6.04B | 5.86B | 1.25B | 691.30M | 636.90M | 4.91B |
| Cost of Revenue | 4.60B | 4.91B | 4.88B | 4.31B | 4.12B | 4.04B | 814.60M | 371.60M | 374.70M | 2.31B |
| Gross Profit | 2.36B | 2.60B | 2.50B | 2.08B | 1.92B | 1.82B | 432.80M | 319.70M | 262.20M | 2.60B |
| Gross Profit Ratio | 33.93% | 34.65% | 33.88% | 32.54% | 31.80% | 31.03% | 34.70% | 46.25% | 41.17% | 53.01% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.10M | 21.90M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.51B | 1.47B | 1.53B | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 201.60M | 1.47B |
| Other Expenses | 0.00 | -800.00K | 10.60M | 9.90M | 2.50M | 3.00M | 3.40M | 200.00K | -300.00K | 0.00 |
| Operating Expenses | 1.66B | 1.47B | 1.53B | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 201.90M | 1.47B |
| Cost & Expenses | 6.26B | 6.38B | 6.41B | 5.69B | 5.49B | 5.45B | 1.46B | 681.40M | 576.60M | 3.78B |
| Interest Income | 0.00 | 265.80M | 229.30M | 307.60M | 440.00M | 0.00 | 0.00 | 0.00 | 30.60M | 0.00 |
| Interest Expense | 284.80M | 265.80M | 217.40M | 307.60M | 440.00M | 523.80M | 200.90M | 80.30M | 0.00 | -265.80M |
| Depreciation & Amortization | 402.30M | 405.50M | 379.20M | 395.40M | 398.90M | 404.60M | 99.20M | 60.30M | 60.70M | 0.00 |
| EBITDA | 1.13B | 1.53B | 1.35B | 765.30M | 879.50M | 814.60M | -91.20M | 70.40M | 121.10M | 1.13B |
| EBITDA Ratio | 16.19% | 20.43% | 18.44% | 17.39% | 15.78% | 14.00% | -8.64% | 10.18% | 19.00% | 23.02% |
| Operating Income | 696.40M | 1.13B | 972.20M | 706.80M | 551.80M | 413.50M | -210.40M | 9.90M | 60.30M | 1.13B |
| Operating Income Ratio | 10.00% | 15.04% | 13.16% | 11.05% | 9.14% | 7.05% | -16.87% | 1.43% | 9.47% | 23.02% |
| Total Other Income/Expenses | -285.90M | -279.10M | -219.20M | -644.50M | -511.20M | -527.30M | -249.80M | -80.50M | -30.50M | -279.10M |
| Income Before Tax | 410.50M | 851.10M | 753.00M | 62.30M | 40.60M | -113.80M | -460.20M | -70.60M | 29.80M | 851.10M |
| Income Before Tax Ratio | 5.89% | 11.33% | 10.19% | 0.97% | 0.67% | -1.94% | -36.89% | -10.21% | 4.68% | 17.34% |
| Income Tax Expense | 89.40M | 164.60M | 180.40M | -54.30M | 2.80M | -26.90M | -314.90M | 10.10M | 17.10M | -164.60M |
| Net Income | 321.10M | 686.50M | 572.60M | 116.60M | 37.80M | -86.90M | -112.70M | -42.40M | 21.60M | 686.50M |
| Net Income Ratio | 4.61% | 9.14% | 7.75% | 1.82% | 0.63% | -1.48% | -9.03% | -6.13% | 3.39% | 13.98% |
| EPS | 0.48 | 1.02 | 0.86 | 0.20 | -0.84 | -0.18 | -0.23 | -0.09 | 0.04 | 1.05 |
| EPS Diluted | 0.47 | 1.01 | 0.85 | 0.20 | -0.84 | -0.18 | -0.23 | -0.09 | 0.04 | 1.01 |
| Weighted Avg Shares Out | 675.60M | 650.90M | 590.50M | 576.30M | 401.20M | 496.50M | 496.50M | 491.30M | 534.29M | 650.90M |
| Weighted Avg Shares Out (Dil) | 678.40M | 679.40M | 599.60M | 583.40M | 401.20M | 496.50M | 496.50M | 491.30M | 534.29M | 679.40M |
BLCO or AVTR: Which Is the Better Value Stock Right Now?
BLCO or AVTR: Which Is the Better Value Stock Right Now?
Avantor® Celebrates Supplier Award Honorees at 2024 European Sales Conference
New Strong Sell Stocks for February 20th
Avantor® to Participate in the 44th Annual TD Cowen Health Care Conference
Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down
Avantor, Inc. (AVTR) Q4 2023 Earnings Call Transcript
Compared to Estimates, Avantor, Inc. (AVTR) Q4 Earnings: A Look at Key Metrics
Avantor® Reports Fourth Quarter and Full Year 2023 Results
Curious about Avantor, Inc. (AVTR) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Source: https://incomestatements.info
Category: Stock Reports